1
|
Kindig K, Gibbs E, Seiferth D, Biggin PC, Chakrapani S. Mechanisms underlying modulation of human GlyRα3 receptors by Zn 2+ and pH. SCIENCE ADVANCES 2024; 10:eadr5920. [PMID: 39693447 DOI: 10.1126/sciadv.adr5920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Accepted: 11/11/2024] [Indexed: 12/20/2024]
Abstract
Glycine receptors (GlyRs) regulate motor control and pain processing in the central nervous system through inhibitory synaptic signaling. The subtype GlyRα3 expressed in nociceptive sensory neurons of the spinal dorsal horn is a key regulator of physiological pain perception. Disruption of spinal glycinergic inhibition is associated with chronic inflammatory pain states, making GlyRα3 an attractive target for pain treatment. GlyRα3 activity is modulated by numerous endogenous and exogenous ligands that consequently affect pain sensitization. To understand the mechanism of two such endogenous modulators, Zn2+ and protons, we have used cryo-electron microscopy to determine structures of full-length human GlyRα3 in various functional states. Whereas acidic pH reduces peak glycine response, Zn2+ displays biphasic modulation in a concentration-dependent manner. Our findings reveal the effector sites and also capture intermediate conformations in the gating cycle. Combined with molecular dynamics simulations and electrophysiology, this work provides important insights into GlyRα3 activation and regulation.
Collapse
Affiliation(s)
- Kayla Kindig
- Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
- Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
| | - Eric Gibbs
- Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
- Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
| | - David Seiferth
- Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK
| | - Philip C Biggin
- Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK
| | - Sudha Chakrapani
- Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
- Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
- Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4970, USA
| |
Collapse
|
2
|
Yan J, Chen L, Warshel A, Bai C. Exploring the Activation Process of the Glycine Receptor. J Am Chem Soc 2024; 146:26297-26312. [PMID: 39279763 DOI: 10.1021/jacs.4c08489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/18/2024]
Abstract
Glycine receptors (GlyR) conduct inhibitory glycinergic neurotransmission in the spinal cord and the brainstem. They play an important role in muscle tone, motor coordination, respiration, and pain perception. However, the mechanism underlying GlyR activation remains unclear. There are five potential glycine binding sites in α1 GlyR, and different binding patterns may cause distinct activation or desensitization behaviors. In this study, we investigated the coupling of protein conformational changes and glycine binding events to elucidate the influence of binding patterns on the activation and desensitization processes of α1 GlyRs. Subsequently, we explored the energetic distinctions between the apical and lateral pathways during α1 GlyR conduction to identify the pivotal factors in the ion conduction pathway preference. Moreover, we predicted the mutational effects of the key residues and verified our predictions using electrophysiological experiments. For the mutants that can be activated by glycine, the predictions of the mutational directions were all correct. The strength of the mutational effects was assessed using Pearson's correlation coefficient, yielding a value of -0.77 between the calculated highest energy barriers and experimental maximum current amplitudes. These findings contribute to our understanding of GlyR activation, identify the key residues of GlyRs, and provide guidance for mechanistic studies on other pLGICs.
Collapse
Affiliation(s)
- Junfang Yan
- School of Medicine, Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen 518172, China
| | - Luonan Chen
- Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China
| | - Arieh Warshel
- Department of Chemistry, University of Southern California, Los Angeles, California 90089-1062, United States
| | - Chen Bai
- School of Medicine, Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen 518172, China
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
- Chenzhu (MoMeD) Biotechnology Co., Ltd., Hangzhou 310005, China
| |
Collapse
|
3
|
Aguayo-Cerón KA, Sánchez-Muñoz F, Gutierrez-Rojas RA, Acevedo-Villavicencio LN, Flores-Zarate AV, Huang F, Giacoman-Martinez A, Villafaña S, Romero-Nava R. Glycine: The Smallest Anti-Inflammatory Micronutrient. Int J Mol Sci 2023; 24:11236. [PMID: 37510995 PMCID: PMC10379184 DOI: 10.3390/ijms241411236] [Citation(s) in RCA: 17] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 06/30/2023] [Indexed: 07/30/2023] Open
Abstract
Glycine is a non-essential amino acid with many functions and effects. Glycine can bind to specific receptors and transporters that are expressed in many types of cells throughout an organism to exert its effects. There have been many studies focused on the anti-inflammatory effects of glycine, including its abilities to decrease pro-inflammatory cytokines and the concentration of free fatty acids, to improve the insulin response, and to mediate other changes. However, the mechanism through which glycine acts is not clear. In this review, we emphasize that glycine exerts its anti-inflammatory effects throughout the modulation of the expression of nuclear factor kappa B (NF-κB) in many cells. Although glycine is a non-essential amino acid, we highlight how dietary glycine supplementation is important in avoiding the development of chronic inflammation.
Collapse
Affiliation(s)
- Karla Aidee Aguayo-Cerón
- Escuela Superior de Medicina, Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de Mexico 11340, Mexico
| | - Fausto Sánchez-Muñoz
- Departamento de Inmunología, Instituto Nacional de Cardiología "Ignacio Chávez", Ciudad de Mexico 14080, Mexico
| | | | | | - Aurora Vanessa Flores-Zarate
- Escuela Superior de Medicina, Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de Mexico 11340, Mexico
| | - Fengyang Huang
- Laboratorio de Investigación en Obesidad y Asma, Hospital Infantil de México Federico Gómez, Ciudad de Mexico 06720, Mexico
| | - Abraham Giacoman-Martinez
- Laboratorio de Framacología, Departamaneto de Ciencias de la Salud, DCBS, Universidad Autónoma Mteropolitana-Iztapalapa (UAM-I), Ciudad de Mexico 09340, Mexico
| | - Santiago Villafaña
- Escuela Superior de Medicina, Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de Mexico 11340, Mexico
| | - Rodrigo Romero-Nava
- Escuela Superior de Medicina, Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de Mexico 11340, Mexico
| |
Collapse
|
4
|
Bilska-Markowska M, Kaźmierczak M. Horner-Wadsworth-Emmons reaction as an excellent tool in the synthesis of fluoro-containing biologically important compounds. Org Biomol Chem 2023; 21:1095-1120. [PMID: 36632995 DOI: 10.1039/d2ob01969h] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Selective introduction of a double bond motif into a multifunctional organic compound is always a big challenge. The Horner-Wadsworth-Emmons reaction is one of the most reliable, simple, and stereoselective olefination methods, widely used in organic chemistry. To the best of our knowledge, no review article on the application of HWE reaction in the synthesis of fluoroorganic compounds with direct biological interest has been published in recent years. The importance of the HWE reaction should be emphasised due to its simplicity and stereoselectivity. Under mild conditions and in one step, valuable compounds can be obtained. The HWE reaction is primarily a great tool in the synthesis of fluoroolefins that are, among others, peptide bond mimetics. Therefore, it can serve as an indispensable approach to access peptide bioisosteres and, consequently, analogues of numerous enzyme inhibitors. The protocol may be utilized to obtain florinated vinylphosphonate, vinylsulfone or sulfonate derivatives, which exhibit biological activity. In this review article, we would like to summarize the HWE reaction output of the last 12 years (since 2010).
Collapse
Affiliation(s)
- Monika Bilska-Markowska
- Faculty of Chemistry, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.
| | - Marcin Kaźmierczak
- Faculty of Chemistry, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland. .,Centre for Advanced Technologies, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 10, 61-614 Poznań, Poland
| |
Collapse
|
5
|
Gallagher CI, Ha DA, Harvey RJ, Vandenberg RJ. Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies. Pharmacol Rev 2022; 74:933-961. [PMID: 36779343 PMCID: PMC9553105 DOI: 10.1124/pharmrev.122.000583] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 04/26/2022] [Accepted: 05/13/2022] [Indexed: 11/22/2022] Open
Abstract
Glycine receptors are ligand-gated ion channels that mediate synaptic inhibition throughout the mammalian spinal cord, brainstem, and higher brain regions. They have recently emerged as promising targets for novel pain therapies due to their ability to produce antinociception by inhibiting nociceptive signals within the dorsal horn of the spinal cord. This has greatly enhanced the interest in developing positive allosteric modulators of glycine receptors. Several pharmaceutical companies and research facilities have attempted to identify new therapeutic leads by conducting large-scale screens of compound libraries, screening new derivatives from natural sources, or synthesizing novel compounds that mimic endogenous compounds with antinociceptive activity. Advances in structural techniques have also led to the publication of multiple high-resolution structures of the receptor, highlighting novel allosteric binding sites and providing additional information for previously identified binding sites. This has greatly enhanced our understanding of the functional properties of glycine receptors and expanded the structure activity relationships of novel pharmacophores. Despite this, glycine receptors are yet to be used as drug targets due to the difficulties in obtaining potent, selective modulators with favorable pharmacokinetic profiles that are devoid of side effects. This review presents a summary of the structural basis for how current compounds cause positive allosteric modulation of glycine receptors and discusses their therapeutic potential as analgesics. SIGNIFICANCE STATEMENT: Chronic pain is a major cause of disability, and in Western societies, this will only increase as the population ages. Despite the high level of prevalence and enormous socioeconomic burden incurred, treatment of chronic pain remains limited as it is often refractory to current analgesics, such as opioids. The National Institute for Drug Abuse has set finding effective, safe, nonaddictive strategies to manage chronic pain as their top priority. Positive allosteric modulators of glycine receptors may provide a therapeutic option.
Collapse
Affiliation(s)
- Casey I Gallagher
- Molecular Biomedicine, School of Medical Sciences, University of Sydney, Sydney, Australia (C.I.G., D.A.H., R.J.V.) and Biomedical Science, School of Health and Behavioural Sciences and Sunshine Coast Health Institute, University of the Sunshine Coast, Maroochydore, Australia (R.J.H.)
| | - Damien A Ha
- Molecular Biomedicine, School of Medical Sciences, University of Sydney, Sydney, Australia (C.I.G., D.A.H., R.J.V.) and Biomedical Science, School of Health and Behavioural Sciences and Sunshine Coast Health Institute, University of the Sunshine Coast, Maroochydore, Australia (R.J.H.)
| | - Robert J Harvey
- Molecular Biomedicine, School of Medical Sciences, University of Sydney, Sydney, Australia (C.I.G., D.A.H., R.J.V.) and Biomedical Science, School of Health and Behavioural Sciences and Sunshine Coast Health Institute, University of the Sunshine Coast, Maroochydore, Australia (R.J.H.)
| | - Robert J Vandenberg
- Molecular Biomedicine, School of Medical Sciences, University of Sydney, Sydney, Australia (C.I.G., D.A.H., R.J.V.) and Biomedical Science, School of Health and Behavioural Sciences and Sunshine Coast Health Institute, University of the Sunshine Coast, Maroochydore, Australia (R.J.H.)
| |
Collapse
|
6
|
Simard JR, Michelsen K, Wang Y, Yang C, Youngblood B, Grubinska B, Taborn K, Gillie DJ, Cook K, Chung K, Long AM, Hall BE, Shaffer PL, Foti RS, Gingras J. Modulation of Ligand-Gated Glycine Receptors Via Functional Monoclonal Antibodies. J Pharmacol Exp Ther 2022; 383:56-69. [PMID: 35926871 DOI: 10.1124/jpet.121.001026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 07/15/2022] [Accepted: 07/19/2022] [Indexed: 12/15/2022] Open
Abstract
Ion channels are targets of considerable therapeutic interest to address a wide variety of neurologic indications, including pain perception. Current pharmacological strategies have focused mostly on small molecule approaches that can be limited by selectivity requirements within members of a channel family or superfamily. Therapeutic antibodies have been proposed, designed, and characterized to alleviate this selectivity limitation; however, there are no Food and Drug Administration-approved therapeutic antibody-based drugs targeting ion channels on the market to date. Here, in an effort to identify novel classes of engineered ion channel modulators for potential neurologic therapeutic applications, we report the generation and characterization of six (EC50 < 25nM) Cys-loop receptor family monoclonal antibodies with modulatory function against rat and human glycine receptor alpha 1 (GlyRα1) and/or GlyRα3. These antibodies have activating (i.e., positive modulator) or inhibiting (i.e., negative modulator) profiles. Moreover, GlyRα3 selectivity was successfully achieved for two of the three positive modulators identified. When dosed intravenously, the antibodies achieved sufficient brain exposure to cover their calculated in vitro EC50 values. When compared head-to-head at identical exposures, the GlyRα3-selective antibody showed a more desirable safety profile over the nonselective antibody, thus demonstrating, for the first time, an advantage for GlyRα3-selectivity. Our data show that ligand-gated ion channels of the glycine receptor family within the central nervous system can be functionally modulated by engineered biologics in a dose-dependent manner and that, despite high protein homology between the alpha subunits, selectivity can be achieved within this receptor family, resulting in future therapeutic candidates with more desirable drug safety profiles. SIGNIFICANCE STATEMENT: This study presents immunization and multiplatform screening approaches to generate a diverse library of functional antibodies (agonist, potentiator, or inhibitory) raised against human glycine receptors (GlyRs). This study also demonstrates the feasibility of acquiring alpha subunit selectivity, a desirable therapeutic profile. When tested in vivo, these tool molecules demonstrated an increased safety profile in favor of GlyRα3-selectivity. These are the first reported functional GlyR antibodies that may open new avenues to treating central nervous system diseases with subunit selective biologics.
Collapse
Affiliation(s)
- Jeffrey R Simard
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Klaus Michelsen
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Yan Wang
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Chunhua Yang
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Beth Youngblood
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Barbara Grubinska
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Kristin Taborn
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Daniel J Gillie
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Kevin Cook
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Kyu Chung
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Alexander M Long
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Brian E Hall
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Paul L Shaffer
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Robert S Foti
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| | - Jacinthe Gingras
- Departments of Neuroscience (J.R.S., C.Y., B.Y. B.G., K.T., D.J.G., J.G.), Molecular Engineering (K.M., A.M.L., P.L.S.), Protein Technologies (Y.W., B.E.H.), and Pharmacokinetics and Drug Metabolism (R.S.F.), Amgen Research, Cambridge, Massachusetts; and Department of Pharmacokinetics and Drug Metabolism, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California (K.Co., K.Ch.)
| |
Collapse
|
7
|
Peiser-Oliver JM, Evans S, Adams DJ, Christie MJ, Vandenberg RJ, Mohammadi SA. Glycinergic Modulation of Pain in Behavioral Animal Models. Front Pharmacol 2022; 13:860903. [PMID: 35694265 PMCID: PMC9174897 DOI: 10.3389/fphar.2022.860903] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 04/19/2022] [Indexed: 11/16/2022] Open
Abstract
Animal models of human pain conditions allow for detailed interrogation of known and hypothesized mechanisms of pain physiology in awake, behaving organisms. The importance of the glycinergic system for pain modulation is well known; however, manipulation of this system to treat and alleviate pain has not yet reached the sophistication required for the clinic. Here, we review the current literature on what animal behavioral studies have allowed us to elucidate about glycinergic pain modulation, and the progress toward clinical treatments so far. First, we outline the animal pain models that have been used, such as nerve injury models for neuropathic pain, chemogenic pain models for acute and inflammatory pain, and other models that mimic painful human pathologies such as diabetic neuropathy. We then discuss the genetic approaches to animal models that have identified the crucial glycinergic machinery involved in neuropathic and inflammatory pain. Specifically, two glycine receptor (GlyR) subtypes, GlyRα1(β) and GlyRα3(β), and the two glycine transporters (GlyT), GlyT1 and GlyT2. Finally, we review the different pharmacological approaches to manipulating the glycinergic system for pain management in animal models, such as partial vs. full agonism, reversibility, and multi-target approaches. We discuss the benefits and pitfalls of using animal models in drug development broadly, as well as the progress of glycinergic treatments from preclinical to clinical trials.
Collapse
Affiliation(s)
| | - Sally Evans
- School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia
| | - David J. Adams
- Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Wollongong, NSW, Australia
| | | | | | - Sarasa A. Mohammadi
- School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia
- *Correspondence: Sarasa A. Mohammadi,
| |
Collapse
|
8
|
Oliveras JM, Puig de la Bellacasa R, Estrada-Tejedor R, Teixidó J, Borrell JI. 1,6-Naphthyridin-2(1 H)-ones: Synthesis and Biomedical Applications. Pharmaceuticals (Basel) 2021; 14:1029. [PMID: 34681253 PMCID: PMC8539032 DOI: 10.3390/ph14101029] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Revised: 10/01/2021] [Accepted: 10/04/2021] [Indexed: 12/20/2022] Open
Abstract
Naphthyridines, also known as diazanaphthalenes, are a group of heterocyclic compounds that include six isomeric bicyclic systems containing two pyridine rings. 1,6-Naphthyridines are one of the members of such a family capable of providing ligands for several receptors in the body. Among such structures, 1,6-naphthyridin-2(1H)-ones (7) are a subfamily that includes more than 17,000 compounds (with a single or double bond between C3 and C4) included in more than 1000 references (most of them patents). This review will cover the analysis of the diversity of the substituents present at positions N1, C3, C4, C5, C7, and C8 of 1,6-naphthyridin-2(1H)-ones, the synthetic methods used for their synthesis (both starting from a preformed pyridine or pyridone ring), and the biomedical applications of such compounds.
Collapse
Affiliation(s)
| | | | | | | | - José I. Borrell
- Grup de Química Farmacèutica, IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, E-08017 Barcelona, Spain; (J.M.O.); (R.P.d.l.B.); (R.E.-T.); (J.T.)
| |
Collapse
|
9
|
Savych VI, Mykhalchuk VL, Melnychuk PV, Isakov AO, Savchuk T, Timoshenko VM, Siry SA, Pavlenko SO, Kovalenko DV, Hryshchuk OV, Reznik VA, Chalyk BA, Yarmolchuk VS, Rusanov EB, Mykhailiuk PK. Bicyclic Pyrrolidines for Medicinal Chemistry via [3 + 2]-Cycloaddition. J Org Chem 2021; 86:13289-13309. [PMID: 34428062 DOI: 10.1021/acs.joc.1c01327] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A general approach to bicyclic fused pyrrolidines via [3 + 2]-cycloaddition between nonstabilized azomethyne ylide and endocyclic electron-deficient alkenes was elaborated. "Push-pull" alkenes and CF3-alkenes did not react with the azomethyne ylide under the previously reported conditions, and we developed a superior protocol (LiF, 140 °C, no solvent). Among obtained products were medchem-relevant bicyclic sulfones, monofluoro-, difluoro-, and trifluoromethyl-substituted pyrrolidines. This approach not only allowed preparation of novel molecules but also significantly simplified synthesis of the existing ones (e.g., sofinicline).
Collapse
Affiliation(s)
- Vladimir I Savych
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | | | - Pavlo V Melnychuk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Andrii O Isakov
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Taras Savchuk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Vadim M Timoshenko
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | - Sergiy A Siry
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | - Sergiy O Pavlenko
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | | | | | - Vitalii A Reznik
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Bohdan A Chalyk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net.,Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | | | - Eduard B Rusanov
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | | |
Collapse
|
10
|
Chatzigoulas A, Cournia Z. Rational design of allosteric modulators: Challenges and successes. WIRES COMPUTATIONAL MOLECULAR SCIENCE 2021. [DOI: 10.1002/wcms.1529] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Alexios Chatzigoulas
- Biomedical Research Foundation Academy of Athens Athens Greece
- Department of Informatics and Telecommunications National and Kapodistrian University of Athens Athens Greece
| | - Zoe Cournia
- Biomedical Research Foundation Academy of Athens Athens Greece
| |
Collapse
|
11
|
Zeilhofer HU, Werynska K, Gingras J, Yévenes GE. Glycine Receptors in Spinal Nociceptive Control-An Update. Biomolecules 2021; 11:846. [PMID: 34204137 PMCID: PMC8228028 DOI: 10.3390/biom11060846] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/03/2021] [Accepted: 06/03/2021] [Indexed: 12/12/2022] Open
Abstract
Diminished inhibitory control of spinal nociception is one of the major culprits of chronic pain states. Restoring proper synaptic inhibition is a well-established rational therapeutic approach explored by several pharmaceutical companies. A particular challenge arises from the need for site-specific intervention to avoid deleterious side effects such as sedation, addiction, or impaired motor control, which would arise from wide-range facilitation of inhibition. Specific targeting of glycinergic inhibition, which dominates in the spinal cord and parts of the hindbrain, may help reduce these side effects. Selective targeting of the α3 subtype of glycine receptors (GlyRs), which is highly enriched in the superficial layers of the spinal dorsal horn, a key site of nociceptive processing, may help to further narrow down pharmacological intervention on the nociceptive system and increase tolerability. This review provides an update on the physiological properties and functions of α3 subtype GlyRs and on the present state of related drug discovery programs.
Collapse
Affiliation(s)
- Hanns Ulrich Zeilhofer
- Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland;
- Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Vladimir Prelog Weg, CH-8093 Zürich, Switzerland
- Drug Discovery Network Zurich, University of Zurich and ETH Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
| | - Karolina Werynska
- Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland;
| | - Jacinthe Gingras
- Homology Medicines Inc., 1 Patriots Park, Bedford, MA 01730, USA;
| | - Gonzalo E. Yévenes
- Department of Physiology, University of Concepción, Concepción 4070386, Chile;
- Millennium Nucleus for the Study of Pain (MiNuSPain), Santiago 8320000, Chile
| |
Collapse
|
12
|
Zhao QK, Wu X, Yang F, Yan PC, Xie JH, Zhou QL. Catalytic Asymmetric Hydrogenation of 3-Ethoxycarbonyl Quinolin-2-ones and Coumarins. Org Lett 2021; 23:3593-3598. [PMID: 33872510 DOI: 10.1021/acs.orglett.1c00993] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A protocol of iridium catalyzed asymmetric hydrogenation of 4-alkyl substituted 3-ethoxycarbonyl quinolin-2-ones and coumarins has been reported, providing a wide range of chiral dihydroquinolin-2-ones and dihydrocoumarins in high yields with excellent enantioselectivities (up to 99% ee) and high turnover numbers (up to 28 000). This efficient protocol was successfully applied for the synthesis of MPR3160 and the key chiral intermediate of R-106578.
Collapse
Affiliation(s)
- Qian-Kun Zhao
- State Key Laboratory and Institute of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
| | - Xiong Wu
- State Key Laboratory and Institute of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
| | - Fan Yang
- State Key Laboratory and Institute of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
| | - Pu-Cha Yan
- Raybow (Hangzhou) Pharmaceutical Science & Technology CO., Ltd., Hangzhou 310018, China
| | - Jian-Hua Xie
- State Key Laboratory and Institute of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
| | - Qi-Lin Zhou
- State Key Laboratory and Institute of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
| |
Collapse
|
13
|
Li F, Egea PF, Vecchio AJ, Asial I, Gupta M, Paulino J, Bajaj R, Dickinson MS, Ferguson-Miller S, Monk BC, Stroud RM. Highlighting membrane protein structure and function: A celebration of the Protein Data Bank. J Biol Chem 2021; 296:100557. [PMID: 33744283 PMCID: PMC8102919 DOI: 10.1016/j.jbc.2021.100557] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Revised: 02/10/2021] [Accepted: 03/16/2021] [Indexed: 12/13/2022] Open
Abstract
Biological membranes define the boundaries of cells and compartmentalize the chemical and physical processes required for life. Many biological processes are carried out by proteins embedded in or associated with such membranes. Determination of membrane protein (MP) structures at atomic or near-atomic resolution plays a vital role in elucidating their structural and functional impact in biology. This endeavor has determined 1198 unique MP structures as of early 2021. The value of these structures is expanded greatly by deposition of their three-dimensional (3D) coordinates into the Protein Data Bank (PDB) after the first atomic MP structure was elucidated in 1985. Since then, free access to MP structures facilitates broader and deeper understanding of MPs, which provides crucial new insights into their biological functions. Here we highlight the structural and functional biology of representative MPs and landmarks in the evolution of new technologies, with insights into key developments influenced by the PDB in magnifying their impact.
Collapse
Affiliation(s)
- Fei Li
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA; Department of Neurology, University of California San Francisco, San Francisco, California, USA
| | - Pascal F Egea
- Department of Biological Chemistry, School of Medicine, University of California Los Angeles, Los Angeles, California, USA
| | - Alex J Vecchio
- Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, USA
| | | | - Meghna Gupta
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA
| | - Joana Paulino
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA
| | - Ruchika Bajaj
- Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA
| | - Miles Sasha Dickinson
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA
| | - Shelagh Ferguson-Miller
- Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, USA
| | - Brian C Monk
- Sir John Walsh Research Institute and Department of Oral Sciences, University of Otago, North Dunedin, Dunedin, New Zealand
| | - Robert M Stroud
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
| |
Collapse
|
14
|
Ben Salah S, Sanselme M, Champavier Y, Othman M, Daïch A, Chataigner I, Martin Lawson A. Five‐Membered Nitrogen Heterocycles Synthesis through 1,3‐Dipolar Cycloaddition of Non‐Stabilized Azomethine Ylides with 2‐Pyridone Heteroaromatic Systems as Dipolarophiles. European J Org Chem 2020. [DOI: 10.1002/ejoc.202001404] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Sami Ben Salah
- Normandie Université, France UNILEHAVRE, URCOM, EA 3212, INC3 M, FR 3038 CNRS 76600 Le Havre France
| | - Morgane Sanselme
- Normandie Université, France UNIROUEN, Laboratoire SMS EA 3233 1 rue Tesnière, 76821 Mont Saint Aignan France
| | - Yves Champavier
- PEIRENE EA 7500/BISCEm, US042 INSERM, UMS2015 CNRS Centre de Biologie Recherche et Santé 2 rue du Dr Marcland 87025 Limoges Cedex France
| | - Mohamed Othman
- Normandie Université, France UNILEHAVRE, URCOM, EA 3212, INC3 M, FR 3038 CNRS 76600 Le Havre France
| | - Adam Daïch
- Normandie Université, France UNILEHAVRE, URCOM, EA 3212, INC3 M, FR 3038 CNRS 76600 Le Havre France
| | - Isabelle Chataigner
- Normandie Université INSA Rouen, UNIROUEN, CNRS, COBRA Laboratory 76000 Rouen France
- CNRS Sorbonne Université LCT UMR 7616 75005 Paris France
| | - Ata Martin Lawson
- Normandie Université, France UNILEHAVRE, URCOM, EA 3212, INC3 M, FR 3038 CNRS 76600 Le Havre France
| |
Collapse
|
15
|
Mondal S, Malakar S. Synthesis of sulfonamide and their synthetic and therapeutic applications: Recent advances. Tetrahedron 2020. [DOI: 10.1016/j.tet.2020.131662] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
16
|
The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. Neuropharmacology 2020; 182:108371. [PMID: 33122032 DOI: 10.1016/j.neuropharm.2020.108371] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 09/04/2020] [Accepted: 10/23/2020] [Indexed: 12/29/2022]
Abstract
GABAA and glycine receptors mediate fast synaptic inhibitory neurotransmission. Despite studies showing that activation of cerebral glycine receptors could be a potential strategy in the treatment of epilepsy, few studies have assessed the effects of existing anticonvulsant therapies on recombinant or native glycine receptors. We, therefore, evaluated the actions of a series of anticonvulsants at recombinant human homo-oligomeric glycine receptor α1, α2 and α3 subtypes expressed in Xenopus oocytes using two-electrode voltage-clamp methods, and then assessed the most effective drug at native glycine receptors from entorhinal cortex neurons using whole-cell voltage-clamp recordings. Ganaxolone, tiagabine and zonisamide positively modulated glycine induced currents at recombinant homomeric glycine receptors. Of these, zonisamide was the most efficacious and exhibited an EC50 value ranging between 450 and 560 μM at α1, α2 and α3 subtypes. These values were not significantly different indicating a non-selective modulation of glycine receptors. Using a therapeutic concentration of zonisamide (100 μM), the potency of glycine was significantly shifted from 106 to 56 μM at α1, 185 to 112 μM at α2, and 245 to 91 μM at α3 receptors. Furthermore, zonisamide (100 μM) potentiated exogenous homomeric and heteromeric glycine mediated currents from layer II pyramidal cells of the lateral or medial entorhinal cortex. As therapeutic concentrations of zonisamide positively modulate recombinant and native glycine receptors, we propose that the anticonvulsant effects of zonisamide may, at least in part, be mediated via this action.
Collapse
|
17
|
Han B, Salituro FG, Blanco MJ. Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities. ACS Med Chem Lett 2020; 11:1810-1819. [PMID: 33062158 DOI: 10.1021/acsmedchemlett.9b00655] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Accepted: 03/10/2020] [Indexed: 01/04/2023] Open
Abstract
Recent years have seen an unprecedented level of innovation in allosteric drug discovery and development, with multiple drug candidates advancing into clinical studies. From early examples of allosteric drugs like GABAA receptor modulators (benzodiazepines) in the 1960s to more recent GPCR negative allosteric modulators of CCR5 (maraviroc) approved in 2007, the opportunities for interrogating allosteric sites in drug discovery have expanded to other target classes such as protein-protein interactions, kinases, and nuclear hormone receptors. In this Innovation Letter, the authors highlight the latest advances of allosteric drug discovery from different target classes and novel emerging chemical modalities beyond small molecules.
Collapse
Affiliation(s)
- Bingsong Han
- Medicinal Chemistry. Sage Therapeutics, Inc., 215 First Street, Cambridge, Massachusetts 02142, United States
| | - Francesco G. Salituro
- Medicinal Chemistry. Sage Therapeutics, Inc., 215 First Street, Cambridge, Massachusetts 02142, United States
| | - Maria-Jesus Blanco
- Medicinal Chemistry. Sage Therapeutics, Inc., 215 First Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
18
|
A facile access to 2-substituted naphtho[2,3-g]quinoline-3-carboxylic acid esters via intramolecular cyclization and PyBOP-promoted functionalization. Tetrahedron 2020. [DOI: 10.1016/j.tet.2020.131418] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
19
|
Abstract
The inhibitory glycine receptor is a member of the Cys-loop superfamily of ligand-gated ion channels. It is the principal mediator of rapid synaptic inhibition in the spinal cord and brainstem and plays an important role in the modulation of higher brain functions including vision, hearing, and pain signaling. Glycine receptor function is controlled by only a few agonists, while the number of antagonists and positive or biphasic modulators is steadily increasing. These modulators are important for the study of receptor activation and regulation and have found clinical interest as potential analgesics and anticonvulsants. High-resolution structures of the receptor have become available recently, adding to our understanding of structure-function relationships and revealing agonistic, inhibitory, and modulatory sites on the receptor protein. This Review presents an overview of compounds that activate, inhibit, or modulate glycine receptor function in vitro and in vivo.
Collapse
Affiliation(s)
- Ulrike Breitinger
- Department of Biochemistry, German University in Cairo, New Cairo 11835, Egypt
| | | |
Collapse
|
20
|
Lara CO, Burgos CF, Moraga-Cid G, Carrasco MA, Yévenes GE. Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain. Front Pharmacol 2020; 11:167. [PMID: 32218730 PMCID: PMC7079299 DOI: 10.3389/fphar.2020.00167] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 02/07/2020] [Indexed: 12/31/2022] Open
Abstract
Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies have proposed new therapeutic strategies focused on the pharmacological modulation of G-protein-coupled receptors, transporters, enzymes, and ion channels expressed on the nociceptive pathways. The present work intends to summarize recent advances on the pharmacological modulation of pentameric ligand-gated ion channels, which plays a key role in pain processing. Experimental data have shown that novel allosteric modulators targeting the excitatory nicotinic acetylcholine receptor, as well as the inhibitory GABAA and glycine receptors, reverse chronic pain-related behaviors in preclinical assays. Collectively, these evidences strongly suggest the pharmacological modulation of pentameric ligand-gated ion channels is a promising strategy towards the development of novel therapeutics to treat chronic pain states in humans.
Collapse
Affiliation(s)
- César O Lara
- Department of Physiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| | - Carlos F Burgos
- Department of Physiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| | - Gustavo Moraga-Cid
- Department of Physiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| | - Mónica A Carrasco
- Department of Biomedical Sciences, Faculty of Health Sciences, University of Talca, Talca, Chile
| | - Gonzalo E Yévenes
- Department of Physiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| |
Collapse
|
21
|
Elmehriki AAH, Gleason JL. A Spiroalkylation Method for the Stereoselective Construction of α-Quaternary Carbons and Its Application to the Total Synthesis of ( R)-Puraquinonic Acid. Org Lett 2019; 21:9729-9733. [PMID: 31756114 DOI: 10.1021/acs.orglett.9b03887] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Cyclic α-quaternary carbon stereocenters were prepared from biselectrophillic substrates and an easily prepared chiral bicyclic sulfonyl lactam. This was achieved in two steps by spiroalkylation, employing biphasic reaction conditions with a phase-transfer catalyst, followed by reduction and alkylation with a series of alkyl halide electrophiles. The products of this method were isolated in good yields with with high levels of diastereoselectivity. This methodology was employed in the enantioselective total synthesis of (R)-puraquinonic acid (1) for a late-stage installation of the α-quaternary carbon stereocenter. This enabled the shortest synthesis of 1 to date, an eight-pot sequence providing an overall yield of 14%.
Collapse
Affiliation(s)
- Adam A H Elmehriki
- Department of Chemistry , McGill University , 801 Sherbrooke Street West , Montreal , Quebec H3A 0B8 , Canada
| | - James L Gleason
- Department of Chemistry , McGill University , 801 Sherbrooke Street West , Montreal , Quebec H3A 0B8 , Canada
| |
Collapse
|
22
|
Jia Z, Hu X, Zhao Y, Qiu FG, Chan ASC, Zhao J. One-Pot Enantioselective Synthesis of 2-Pyrrolidinone Derivatives Bearing a Trifluoromethylated All-Carbon Quaternary Stereocenter. Org Lett 2019; 21:9584-9588. [DOI: 10.1021/acs.orglett.9b03758] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Zhuqing Jia
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, P. R. China
- University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Xiaoyi Hu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, P. R. China
- University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Yunlong Zhao
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, P. R. China
| | - Fayang G. Qiu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, P. R. China
| | - Albert S. C. Chan
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, P. R. China
| | - Junling Zhao
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, P. R. China
| |
Collapse
|
23
|
Bressin RK, Driscoll JL, Wang Y, Koide K. Scalable Preparation of Methylated Ando-Type Horner–Wadsworth–Emmons Reagent. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.8b00423] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Robert K. Bressin
- Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States
| | - Julia L. Driscoll
- Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States
| | - Yanping Wang
- Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States
| | - Kazunori Koide
- Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States
| |
Collapse
|
24
|
Mykhalchuk VL, Yarmolchuk VS, Doroschuk RO, Tolmachev AA, Grygorenko OO. [3+2] Cycloaddition of an Azomethyne Ylide and Vinyl Sulfonyl Fluorides ― an Approach to Pyrrolidine-3-sulfonyl Fluorides. European J Org Chem 2018. [DOI: 10.1002/ejoc.201800521] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Volodymyr L. Mykhalchuk
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- National Taras Shevchenko University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Vladimir S. Yarmolchuk
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- National Taras Shevchenko University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Roman O. Doroschuk
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- National Taras Shevchenko University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Andrey A. Tolmachev
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- National Taras Shevchenko University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Oleksandr O. Grygorenko
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- National Taras Shevchenko University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| |
Collapse
|
25
|
Zeilhofer HU, Acuña MA, Gingras J, Yévenes GE. Glycine receptors and glycine transporters: targets for novel analgesics? Cell Mol Life Sci 2018; 75:447-465. [PMID: 28791431 PMCID: PMC11105467 DOI: 10.1007/s00018-017-2622-x] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 07/14/2017] [Accepted: 08/04/2017] [Indexed: 01/29/2023]
Abstract
Glycinergic neurotransmission has long been known for its role in spinal motor control. During the last two decades, additional functions have become increasingly recognized-among them is a critical contribution to spinal pain processing. Studies in rodent pain models provide proof-of-concept evidence that enhancing inhibitory glycinergic neurotransmission reduces chronic pain symptoms. Apparent strategies for pharmacological intervention include positive allosteric modulators of glycine receptors and modulators or inhibitors of the glial and neuronal glycine transporters GlyT1 and GlyT2. These prospects have led to drug discovery efforts in academia and in industry aiming at compounds that target glycinergic neurotransmission with high specificity. Available data show promising analgesic efficacy. Less is currently known about potential unwanted effects but the presence of glycinergic innervation in CNS areas outside the nociceptive system prompts for a careful evaluation not only of motor function, but also of potential respiratory impairment and addictive properties.
Collapse
Affiliation(s)
- Hanns Ulrich Zeilhofer
- Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
- Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Vladimir-Prelog-Weg 1-5/10, 8093, Zurich, Switzerland.
| | - Mario A Acuña
- Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland
| | | | - Gonzalo E Yévenes
- Department of Physiology, University of Concepción, Concepción, Chile
| |
Collapse
|
26
|
Cioffi CL. Modulation of Glycine-Mediated Spinal Neurotransmission for the Treatment of Chronic Pain. J Med Chem 2017; 61:2652-2679. [PMID: 28876062 DOI: 10.1021/acs.jmedchem.7b00956] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Chronic pain constitutes a significant and expanding worldwide health crisis. Currently available analgesics poorly serve individuals suffering from chronic pain, and new therapeutic agents that are more effective, safer, and devoid of abuse liabilities are desperately needed. Among the myriad of cellular and molecular processes contributing to chronic pain, spinal disinhibition of pain signaling to higher cortical centers plays a critical role. Accumulating evidence shows that glycinergic inhibitory neurotransmission in the spinal cord dorsal horn gates nociceptive signaling, is essential in maintaining physiological pain sensitivity, and is diminished in pathological pain states. Thus, it is hypothesized that agents capable of enhancing glycinergic tone within the dorsal horn could obtund nociceptor signaling to the brain and serve as analgesics for persistent pain. This Perspective highlights the potential that pharmacotherapies capable of increasing inhibitory spinal glycinergic neurotransmission hold in providing new and transformative analgesic therapies for the treatment of chronic pain.
Collapse
Affiliation(s)
- Christopher L Cioffi
- Departments of Basic and Clinical Sciences and Pharmaceutical Sciences , Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue , Albany , New York 12208 United States
| |
Collapse
|
27
|
Sparling BA, DiMauro EF. Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors. Bioorg Med Chem Lett 2017; 27:3207-3218. [DOI: 10.1016/j.bmcl.2017.04.073] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Revised: 04/20/2017] [Accepted: 04/24/2017] [Indexed: 12/11/2022]
|
28
|
Chakka N, Andrews KL, Berry LM, Bregman H, Gunaydin H, Huang L, Guzman-Perez A, Plant MH, Simard JR, Gingras J, DiMauro EF. Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators. Eur J Med Chem 2017; 137:63-75. [PMID: 28575722 DOI: 10.1016/j.ejmech.2017.05.036] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/09/2017] [Accepted: 05/11/2017] [Indexed: 12/24/2022]
Abstract
Glycine receptors (GlyRs) are pentameric glycine-gated chloride ion channels that are enriched in the brainstem and spinal cord where they have been demonstrated to play a role in central nervous system (CNS) inhibition. Herein we describe two novel classes of glycine receptor potentiators that have been developed using similarity- and property-guided scaffold hopping enabled by parallel synthesis and pharmacophore-based virtual screening strategies. This effort resulted in the identification of novel, efficient and modular leads having favorable in vitro ADME profiles and high CNS multi-parameter optimization (MPO) scores, exemplified by azetidine sulfonamide 19 and aminothiazole sulfone (ent2)-20.
Collapse
Affiliation(s)
- Nagasree Chakka
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Kristin L Andrews
- Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Loren M Berry
- Department of Pharmacokinetics, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Howard Bregman
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Hakan Gunaydin
- Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Liyue Huang
- Department of Pharmacokinetics, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Angel Guzman-Perez
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Matthew H Plant
- Department of Discovery Attribute Sciences, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Jeffrey R Simard
- Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Jacinthe Gingras
- Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA
| | - Erin F DiMauro
- Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA.
| |
Collapse
|
29
|
Johnstone S, Albert JS. Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett 2017; 27:2239-2258. [PMID: 28408223 DOI: 10.1016/j.bmcl.2017.03.084] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 03/26/2017] [Accepted: 03/27/2017] [Indexed: 12/11/2022]
Abstract
New strategies to potentially improve drug safety and efficacy emerge with allosteric programs. Biased allosteric modulators can be designed with high subtype selectivity and defined receptor signaling endpoints, however, selecting the most meaningful parameters for optimization can be perplexing. Historically, "potency hunting" at the expense of physicochemical and pharmacokinetic optimization has led to numerous tool compounds with excellent pharmacological properties but no path to drug development. Conversely, extensive physicochemical and pharmacokinetic screening with only post hoc bias and allosteric characterization has led to inefficacious compounds or compounds with on-target toxicities. This field is rapidly evolving with new mechanistic understanding, changes in terminology, and novel opportunities. The intent of this digest is to summarize current understanding and debates within the field. We aim to discuss, from a medicinal chemistry perspective, the parameter choices available to drive SAR.
Collapse
Affiliation(s)
- Shawn Johnstone
- Department of Chemistry, IntelliSyn Pharma, 7171 Frederick-Banting, Montreal, Quebec H4S 1Z9, Canada.
| | - Jeffrey S Albert
- Department of Chemistry, IntelliSyn Pharma, 7171 Frederick-Banting, Montreal, Quebec H4S 1Z9, Canada; Department of Chemistry, AviSyn Pharma, 4275 Executive Square, Suite 200, La Jolla, CA 92037, United States.
| |
Collapse
|
30
|
Lynch JW, Zhang Y, Talwar S, Estrada-Mondragon A. Glycine Receptor Drug Discovery. ADVANCES IN PHARMACOLOGY 2017; 79:225-253. [DOI: 10.1016/bs.apha.2017.01.003] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|